The focus of the companies in this partnership is to synergise capabilities, leverage research and bring innovative products in specific therapeutic areas
Gland Pharma enters into a Put Option Agreement to acquire 100% of Cenexi Group
Steve joins Sai Life Sciences from GlaxoSmithKline (GSK) where he was a department head and member of the global chemical development leadership team.
The Group will continue to make proactive investments of its management resources in the life science business
API platform to comprise of RA Chem Pharma, ZCL Chemicals and Avra Laboratories
Through the collaboration, Lonza will gain access to Singzyme’s enzymatic conjugation platform enabling the site-specific binding of payloads with peptidic linkers to proteins of interest
NFIL’s ambition is to reach revenues of US$100mn from CDMO by FY25.
The company currently supplies one product to the US market that contributes low- single digit revenue to Jubilant Pharmova revenue
Gland Pharma Q2 FY2023 consolidated net profit up at Rs. 241.24 Cr
On the Capex front, the company has invested Rs. 416 crore in the first half and it is broadly in line with our guidance for the two years around Rs. 2,000 crore across all the subsidiaries and divisions
Subscribe To Our Newsletter & Stay Updated
